BETHESDA, Md., June 2 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host a webcast on June 8, 2009 to discuss the blinatumomab data presented on June 5th and 6th at the 14th Congress of the European Hematology Association. The webcast will be available on the company's website at www.micromet-inc.com.
Forum: Micromet, Inc. Webcast Investor Meeting Date: Monday, June 8, 2009 Time: 9:00 am to 11:00 am U.S. Eastern Time Webcast: www.micromet-inc.com
To participate in this conference call, dial 866-543-6403 (U.S.) or 617-213-8896 (international), passcode: 12594792. The audio webcast can be accessed at www.micromet-inc.com.
A replay of the call will be available from 1:00 pm Eastern Time on June 8, 2009 (7:00 pm Central European Time) through, June 15, 2009. The replay number is 888-286-8010 (U.S.) or 617-801-6888 (international), passcode: 67386852.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal antibodies. BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's immune system to eliminate cancer cells. Four of Micromet's antibodies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the tr
|SOURCE Micromet, Inc.|
Copyright©2009 PR Newswire.
All rights reserved